Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2017 Dec;76(12):1955-1964.
doi: 10.1136/annrheumdis-2017-211468. Epub 2017 Oct 27.

2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups

Ingrid E Lundberg  1 , Anna Tjärnlund  1 , Matteo Bottai  2 , Victoria P Werth  3 , Clarissa Pilkington  4 , Marianne de Visser  5 , Lars Alfredsson  2 , Anthony A Amato  6 , Richard J Barohn  7 , Matthew H Liang  8 , Jasvinder A Singh  9   10 , Rohit Aggarwal  11 , Snjolaug Arnardottir  12 , Hector Chinoy  13 , Robert G Cooper  14 , Katalin Dankó  15 , Mazen M Dimachkie  7 , Brian M Feldman  16 , Ignacio Garcia-De La Torre  17 , Patrick Gordon  18 , Taichi Hayashi  19 , James D Katz  20 , Hitoshi Kohsaka  21 , Peter A Lachenbruch  22 , Bianca A Lang  23 , Yuhui Li  24 , Chester V Oddis  11 , Marzena Olesinska  25 , Ann M Reed  26 , Lidia Rutkowska-Sak  27 , Helga Sanner  28 , Albert Selva-O'Callaghan  29 , Yeong-Wook Song  30 , Jiri Vencovsky  31 , Steven R Ytterberg  32 , Frederick W Miller  33 , Lisa G Rider  33 ; International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland)
Affiliations
Practice Guideline

2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups

Ingrid E Lundberg et al. Ann Rheum Dis. 2017 Dec.

Erratum in

Abstract

Objective: To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups.

Methods: Candidate variables were assembled from published criteria and expert opinion using consensus methodology. Data were collected from 47 rheumatology, dermatology, neurology and paediatric clinics worldwide. Several statistical methods were used to derive the classification criteria.

Results: Based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% adults; 18% children), new criteria were derived. Each item is assigned a weighted score. The total score corresponds to a probability of having IIM. Subclassification is performed using a classification tree. A probability cut-off of 55%, corresponding to a score of 5.5 (6.7 with muscle biopsy) 'probable IIM', had best sensitivity/specificity (87%/82% without biopsies, 93%/88% with biopsies) and is recommended as a minimum to classify a patient as having IIM. A probability of ≥90%, corresponding to a score of ≥7.5 (≥8.7 with muscle biopsy), corresponds to 'definite IIM'. A probability of <50%, corresponding to a score of <5.3 (<6.5 with muscle biopsy), rules out IIM, leaving a probability of ≥50 to <55% as 'possible IIM'.

Conclusions: The European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology and paediatric groups. They employ easily accessible and operationally defined elements, and have been partially validated. They allow classification of 'definite', 'probable' and 'possible' IIM, in addition to the major subgroups of IIM, including juvenile IIM. They generally perform better than existing criteria.

Keywords: autoimmune diseases; dermatomyositis; polymyositis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta and Allergan. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity. JAS is a member of the executive committee of OMERACT, an organisation that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. HC and RGC’s work in myositis is partly funded by grants from Arthritis Research UK (18474) and the Medical Research Council (MR/N003322/1). JV’s work in myositis is supported by Project (Ministry of Health, Czech Republic) for conceptual development of research organization 00023728.

Figures

Figure 1
Figure 1
Probability of having idiopathic inflammatory myopathies (IIM) based on the EULAR/ACR classification criteria for IIM. Each score obtained from the classification criteria corresponds to a probability of having the disease, without muscle biopsy data (A), or with muscle biopsy data (B). Each score and probability of disease display a unique set of sensitivity (blue line) and specificity (red line) measurements for the classification criteria not including muscle biopsy data (C) or including muscle biopsy data (D). The most optimal point of accuracy should be stated in publications and be appropriate to the intended purpose, with the recommendation of using a minimum of 55% probability (score of 5.5 without biopsies; 6.7 with biopsies) for classifying a case as IIM (“probable IIM”) (dotted line). “Definite IIM” corresponds to a probability of at least 90% (score of 7.5 without biopsies; 8.7 with biopsies).
Figure 1
Figure 1
Probability of having idiopathic inflammatory myopathies (IIM) based on the EULAR/ACR classification criteria for IIM. Each score obtained from the classification criteria corresponds to a probability of having the disease, without muscle biopsy data (A), or with muscle biopsy data (B). Each score and probability of disease display a unique set of sensitivity (blue line) and specificity (red line) measurements for the classification criteria not including muscle biopsy data (C) or including muscle biopsy data (D). The most optimal point of accuracy should be stated in publications and be appropriate to the intended purpose, with the recommendation of using a minimum of 55% probability (score of 5.5 without biopsies; 6.7 with biopsies) for classifying a case as IIM (“probable IIM”) (dotted line). “Definite IIM” corresponds to a probability of at least 90% (score of 7.5 without biopsies; 8.7 with biopsies).
Figure 1
Figure 1
Probability of having idiopathic inflammatory myopathies (IIM) based on the EULAR/ACR classification criteria for IIM. Each score obtained from the classification criteria corresponds to a probability of having the disease, without muscle biopsy data (A), or with muscle biopsy data (B). Each score and probability of disease display a unique set of sensitivity (blue line) and specificity (red line) measurements for the classification criteria not including muscle biopsy data (C) or including muscle biopsy data (D). The most optimal point of accuracy should be stated in publications and be appropriate to the intended purpose, with the recommendation of using a minimum of 55% probability (score of 5.5 without biopsies; 6.7 with biopsies) for classifying a case as IIM (“probable IIM”) (dotted line). “Definite IIM” corresponds to a probability of at least 90% (score of 7.5 without biopsies; 8.7 with biopsies).
Figure 1
Figure 1
Probability of having idiopathic inflammatory myopathies (IIM) based on the EULAR/ACR classification criteria for IIM. Each score obtained from the classification criteria corresponds to a probability of having the disease, without muscle biopsy data (A), or with muscle biopsy data (B). Each score and probability of disease display a unique set of sensitivity (blue line) and specificity (red line) measurements for the classification criteria not including muscle biopsy data (C) or including muscle biopsy data (D). The most optimal point of accuracy should be stated in publications and be appropriate to the intended purpose, with the recommendation of using a minimum of 55% probability (score of 5.5 without biopsies; 6.7 with biopsies) for classifying a case as IIM (“probable IIM”) (dotted line). “Definite IIM” corresponds to a probability of at least 90% (score of 7.5 without biopsies; 8.7 with biopsies).
Figure 2
Figure 2
Classification tree for subgroups of idiopathic inflammatory myopathies (IIM). A patient must first meet the EULAR/ACR classification criteria for IIM (probability of IIM ≥55%). The patient can then be sub-classified using the classification tree. The subgroup of PM patients includes patients with immune-mediated necrotizing myopathy (IMNM). For IBM classification one of the following, *Finger flexor weakness and response to treatment: not improved, or **Muscle biopsy: rimmed vacuoles, is required for diagnosis. ***Juvenile myositis other than JDM was developed based on expert opinion. IMNM and hypomyopathic DM were too few to allow sub-classification. PM, polymyositis; IMNM, immune-mediated necrotizing myopathy; IBM, inclusion body myositis; ADM, amyopathic dermatomyositis; DM, dermatomyositis; JDM, juvenile dermatomyositis.
See this image and copyright information in PMC

Comment in

References

    1. Plotz PH, Rider GL, Targoff IN, et al. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med. 1995;122:715–24. - PubMed
    1. Dalakas MC. Inflammatory muscle diseases. N Eng J Med. 2015;372:1734–47. - PubMed
    1. Rider LG, Giannini EH, Brunner HI, et al. International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50:2281–90. - PubMed
    1. Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52:2607–15. - PubMed
    1. Medsger TA, Jr, Dawson WN, Jr, Masi AT. The epidemiology of polymyositis. Am J Med. 1970;48:715–23. - PubMed

Publication types